See more : Taisun Int’l (Holding) Corporation (8480.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Pluri Inc. (PLUR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pluri Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Trio Resources, Inc. (TRII) Income Statement Analysis – Financial Results
- eBullion, Inc. (EBML) Income Statement Analysis – Financial Results
- Shandong Donghong Pipe Industry Co., Ltd. (603856.SS) Income Statement Analysis – Financial Results
- Signature Resources Ltd. (SGGTD) Income Statement Analysis – Financial Results
- Owlet, Inc. (OWLT) Income Statement Analysis – Financial Results
Pluri Inc. (PLUR)
About Pluri Inc.
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 326.00K | 287.00K | 234.00K | 0.00 | 23.00K | 54.00K | 50.00K | 0.00 | 2.85M | 379.00K | 379.00K | 679.00K | 716.00K | -1.68M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 4.00K | 9.00K | 41.59M | 50.62M | 1.57M | 2.00K | 2.00K | 2.18M | 100.00K | 13.00K | 11.00K | 20.00K | 21.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.00K |
| Gross Profit | 322.00K | 278.00K | -41.36M | -50.62M | -1.55M | 52.00K | 48.00K | -2.18M | 2.75M | 366.00K | 368.00K | 659.00K | 695.00K | -1.68M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -6.00K |
| Gross Profit Ratio | 98.77% | 96.86% | -17,674.79% | 0.00% | -6,726.09% | 96.30% | 96.00% | 0.00% | 96.49% | 96.57% | 97.10% | 97.05% | 97.07% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 12.45M | 15.75M | 24.38M | 30.07M | 21.58M | 26.43M | 22.63M | 21.09M | 19.58M | 19.17M | 19.54M | 17.23M | 9.18M | 6.63M | 4.30M | 3.14M | 4.39M | 2.55M | 1.30M | 1.79M | 1.22M | 79.87K | 0.00 |
| General & Administrative | 10.03M | 11.78M | 17.45M | 20.56M | 7.92M | 9.16M | 11.19M | 6.93M | 6.49M | 6.46M | 8.68M | 5.65M | 6.57M | 4.49M | 3.14M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 112.96K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17.66K | 0.00 |
| SG&A | 10.03M | 11.78M | 17.45M | 20.56M | 7.92M | 9.16M | 11.19M | 6.93M | 6.49M | 6.46M | 8.68M | 5.65M | 6.57M | 4.49M | 3.14M | 3.42M | 6.04M | 3.73M | 1.03M | 873.65K | 1.78M | 130.62K | 74.45K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -43.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 168.62K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 22.48M | 27.52M | 41.83M | 50.62M | 29.50M | 35.58M | 33.78M | 28.02M | 26.07M | 25.63M | 28.22M | 22.88M | 15.75M | 11.11M | 7.44M | 6.56M | 10.43M | 6.28M | 2.33M | 2.83M | 3.00M | 210.49K | 74.45K |
| Cost & Expenses | 22.48M | 27.53M | 41.83M | 50.62M | 29.50M | 35.59M | 33.78M | 28.02M | 26.17M | 25.65M | 28.23M | 22.90M | 15.75M | 11.11M | 7.44M | 6.56M | 10.43M | 6.28M | 2.33M | 2.83M | 3.00M | 210.49K | 74.45K |
| Interest Income | 1.31M | 1.08M | 581.00K | 492.00K | 384.00K | 385.00K | 276.00K | 122.00K | 149.00K | 112.00K | 246.00K | 266.00K | 575.00K | 236.00K | 2.00K | 14.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 866.00K | 843.00K | 887.00K | 78.00K | 196.00K | 29.00K | 937.00K | 0.00 | 100.00K | 37.00K | 36.00K | 29.00K | 12.00K | 13.00K | 31.00K | 8.00K | 0.00 | 23.02K | 0.00 | 0.00 | 0.00 | 0.00 | 3.45K |
| Depreciation & Amortization | 253.00K | 362.00K | 1.05M | 1.37M | 1.57M | 1.96M | 2.02M | 2.18M | 2.15M | 2.07M | 1.90M | 1.03M | 435.00K | 312.00K | 207.00K | 173.00K | 129.00K | 224.72K | 264.83K | 202.85K | 153.64K | 21.04K | 0.00 |
| EBITDA | -20.23M | -27.68M | -39.43M | -48.42M | -27.39M | -33.35M | -24.05M | -25.57M | -21.01M | -22.57M | -25.03M | -21.19M | -14.35M | -10.52M | -7.23M | -6.51M | -10.35M | -7.42M | -2.10M | -1.87M | -1.84M | 0.00 | -74.45K |
| EBITDA Ratio | -6,203.99% | -8,995.12% | -17,087.18% | 0.00% | -119,800.00% | -61,924.07% | -79,958.00% | 0.00% | -743.06% | -6,255.41% | -7,033.25% | -3,081.59% | -2,003.77% | 644.77% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -22.16M | -27.25M | -41.59M | -50.62M | -29.48M | -35.53M | -33.73M | -28.02M | -23.32M | -25.27M | -27.85M | -22.22M | -15.03M | -11.11M | -7.44M | -6.56M | -10.43M | -6.28M | -2.33M | -2.83M | -3.00M | -456.96K | -74.45K |
| Operating Income Ratio | -6,796.93% | -9,493.38% | -17,774.79% | 0.00% | -128,156.52% | -65,800.00% | -67,462.00% | 0.00% | -819.07% | -6,666.75% | -7,348.28% | -3,272.90% | -2,099.30% | 660.76% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 814.00K | -1.64M | 219.00K | 758.00K | 324.00K | 225.00K | 7.61M | 205.00K | 73.00K | 590.00K | 918.00K | 1.07M | 237.00K | 266.00K | -14.00K | -84.00K | -69.00K | -2.15M | -107.46K | 731.65K | 994.18K | 0.00 | 0.00 |
| Income Before Tax | -21.34M | -28.89M | -41.37M | -49.87M | -29.15M | -35.31M | -26.13M | -27.81M | -23.25M | -24.68M | -26.93M | -21.16M | -14.79M | -11.07M | -7.46M | -6.64M | 0.00 | -8.24M | 0.00 | -2.09M | 0.00 | 418.26K | 0.00 |
| Income Before Tax Ratio | -6,547.24% | -10,065.16% | -17,681.20% | 0.00% | -126,747.83% | -65,383.33% | -52,252.00% | 0.00% | -816.51% | -6,511.08% | -7,106.07% | -3,115.61% | -2,066.20% | 658.20% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 277.00K | -351.00K | 78.00K | 196.00K | -94.00K | 7.61M | -205.00K | -73.00K | -590.00K | -918.00K | 29.00K | 249.00K | -266.00K | 14.00K | 78.00K | 69.00K | 2.15M | 107.46K | -731.65K | -994.17K | 252.51K | 77.90K |
| Net Income | -20.89M | -28.32M | -41.02M | -49.94M | -29.35M | -35.21M | -26.13M | -27.81M | -23.25M | -24.68M | -26.93M | -21.16M | -14.79M | -10.85M | -7.45M | -6.64M | -10.50M | -8.43M | -2.44M | -2.10M | -2.01M | -463.00K | -77.90K |
| Net Income Ratio | -6,407.36% | -9,867.94% | -17,531.20% | 0.00% | -127,600.00% | -65,209.26% | -52,252.00% | 0.00% | -816.51% | -6,511.08% | -7,106.07% | -3,115.61% | -2,066.20% | 644.95% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.99 | -6.18 | -10.19 | -14.21 | -12.90 | -22.84 | -19.74 | -25.45 | -23.38 | -28.09 | -33.92 | -30.50 | -26.88 | -27.82 | -35.06 | -50.07 | -130.77 | -467.52 | -639.99 | -822.71 | -120.34 | -27.71 | -4.66 |
| EPS Diluted | -3.99 | -6.18 | -10.19 | -14.21 | -12.90 | -22.84 | -19.74 | -25.45 | -23.38 | -28.09 | -33.92 | -30.50 | -26.88 | -27.82 | -35.06 | -50.07 | -130.77 | -467.52 | -639.99 | -822.71 | -120.34 | -27.71 | -4.66 |
| Weighted Avg Shares Out | 5.24M | 4.58M | 4.02M | 3.51M | 2.27M | 1.54M | 1.32M | 1.09M | 994.35K | 878.55K | 793.93K | 693.52K | 550.40K | 389.99K | 212.56K | 132.54K | 80.28K | 18.03K | 3.81K | 2.55K | 16.71K | 16.71K | 16.71K |
| Weighted Avg Shares Out (Dil) | 5.24M | 4.58M | 4.02M | 3.51M | 2.27M | 1.54M | 1.32M | 1.09M | 994.35K | 878.55K | 793.93K | 693.52K | 550.40K | 389.99K | 212.56K | 132.54K | 80.28K | 18.03K | 3.81K | 2.55K | 16.71K | 16.71K | 16.71K |
Pluristem Appoints Prof. Varda Shalev MD and Mr.
HAIFA, Israel, July 19, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today announced the Board of Director appointments of Prof. Varda Shalev, a physician, medical researcher, and Professor of Medicine at the...
Pluristem Brings ARDS Associated with COVID-19 Phase II Studies to Clinical Readout
HAIFA, Israel, July 08, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (the “Company”), a leading biotechnology company announced today that it is bringing its Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19 Phase II studies to clinical readout....
Cathie Wood's ARK Invest Sells 194,000 Shares of Pluristem Therapeutics
One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold nearly 194,000 shares of Pluristem Therapeutics Inc.
Pluristem Stock is Trading Higher After €20M Non-Dilutive Funding from European Investment Bank
Pluristem Therapeutics Inc (NASDAQ: PSTI) has received €20 million (approximately $24 million) from the European Investment Bank (EIB), the first disbursement of three tranches of funding. The disbursement reflects that Pluristem has achieved a key milestone in a previously announced €50 million non-dilutive financing...
PSTI Stock: From $4.52 To Over $4.90 Pre-Market Explanation
The stock price of Pluristem Therapeutics Inc. (NASDAQ: PSTI) increased from $4.52 to over $4.90 pre-market. This is why it happened.
Longeveron Seeks $25 Million IPO For Anti-Aging Efforts
Longeveron Seeks $25 Million IPO For Anti-Aging Efforts
Pluristem Therapeutics Inc. Announces $30 Million Registered Direct Offering
HAIFA, Israel, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products (“Pluristem” or the “Company”), today announced it has entered into definitive agreements with institutional investors...
ARKG: Potential Disruption For Healthcare And Pharma Industries
ARKG: Potential Disruption For Healthcare And Pharma Industries
Pluristem Enters Collaboration With Pharmaceutical Company Innovare R&D to Expand Pluristem's ARDS Associated With COVID-19 Program to Mexico
HAIFA, Israel, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today it has entered into a collaboration agreement with Mexican pharmaceutical company Innovare...
Pluristem Announces DMC Recommendation Following Interim Analysis of its Phase III CLI Study
HAIFA, Israel, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. ( Nasdaq:PSTI ) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, today announced that the independent Data Monitoring Committee (DMC) of its global...
Source: https://incomestatements.info
Category: Stock Reports